Abstract
SummaryComplement receptor 3 (CR3, CD11b/CD18) is a multi‐functional receptor expressed predominantly on myeloid and natural killer (NK) cells. The R77H variant of CD11b, encoded by the ITGAM rs1143679 polymorphism, is associated robustly with development of the autoimmune disease systemic lupus erythematosus (SLE) and impairs CR3 function, including its regulatory role on monocyte immune signalling. The role of CR3 in NK cell function is unknown. Leukadherin‐1 is a specific small‐molecule CR3 agonist that has shown therapeutic promise in animal models of vascular injury and inflammation. We show that Leukadherin‐1 pretreatment reduces secretion of interferon (IFN)‐γ, tumour necrosis factor (TNF) and macrophage inflammatory protein (MIP)‐1β by monokine‐stimulated NK cells. It was associated with a reduction in phosphorylated signal transducer and activator of transcription (pSTAT)‐5 following interleukin (IL)‐12 + IL‐15 stimulation (P < 0·02) and increased IL‐10 secretion following IL‐12 + IL‐18 stimulation (P < 0·001). Leukadherin‐1 pretreatment also reduces secretion of IL‐1β, IL‐6 and TNF by Toll‐like receptor (TLR)‐2 and TLR‐7/8‐stimulated monocytes (P < 0·01 for all). The R77H variant did not affect NK cell response to Leukadherin‐1 using ex‐vivo cells from homozygous donors; nor did the variant influence CR3 expression by these cell types, in contrast to a recent report. These data extend our understanding of CR3 biology by demonstrating that activation potently modifies innate immune inflammatory signalling, including a previously undocumented role in NK cell function. We discuss the potential relevance of this to the pathogenesis of SLE. Leukadherin‐1 appears to mediate its anti‐inflammatory effect irrespective of the SLE‐risk genotype of CR3, providing further evidence to support its evaluation of Leukadherin‐1 as a potential therapeutic for autoimmune disease.
Highlights
Complement receptor 3 (CR3), known as Mac1 or the aMb2 integrin (CD11b/CD18), is a multi-functional receptor expressed constitutively on neutrophils, myeloid cells and natural killer (NK) cells, as well as on subsets of activated lymphocytes
NK cells release a well-documented repertoire of cytokines, including interferon-g (IFN-g), tumour necrosis factor (TNF), macrophage inflammatory protein-1b [MIP-1b (CCL4)] and interleukin-8 [IL8 (CXCL8)], following activation by synergistic combinations of monokines [20]
Largemagnitude reduction in IFN-g, TNF and MIP-1b secretion by monokine-stimulated (IL-12 1 IL-15, Fig. 1a; IL-12 1 IL18, Fig. 1b) NK cells that had been pretreated with Leukadherin-1 (P < 0Á001 for all; Fig. 1)
Summary
Complement receptor 3 (CR3), known as Mac or the aMb2 integrin (CD11b/CD18), is a multi-functional receptor expressed constitutively on neutrophils, myeloid cells and natural killer (NK) cells, as well as on subsets of activated lymphocytes. It binds a diverse range of ligands, which include iC3b (the stable, biologically active, solid-phase degradation fragment of complement component C3), the intercellular adhesion molecule ICAM-1 and the coagulation protein fibrinogen [1,2]. CR3 has long been recognized as a mediator of cell adhesion and phagocytosis, capable of triggering phagocytosis itself and mediating phagocytosis following ligand engagement by glycophosphatidylinositol (GPI)-linked FcgRIIIB (CD16b) on neutrophils [3]. Clinical and Experimental Immunology published by John Wiley & Sons Ltd on behalf of British
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
